Novel Smallpox Vaccine Derived from VV/VAR Immunome

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,027,410.00
Award Year:
2005
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI058376-01A1
Agency Tracking Number:
AI058376
Solicitation Year:
2005
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2005-2
Small Business Information
EPIVAX, INC.
Epivax, Inc., 146 Clifford Street, Providence, RI, 02903
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
Y
Duns:
n/a
Principal Investigator:
ANNE DEGROOT
(401) 272-2123
annied@epivax.com
Business Contact:
RONITA FISHER
(401) 272-2123
FISHERR@EPIVAX.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): EpiVax specializes in the development of epitope-driven vaccines by screening whole genomes for candidate vaccine components. In this application, we propose to develop a safe, new smallpox vaccine based on epitopes conserved between the vaccinia virus (VV) and Variola (VAR) 'immunomes' that could be used as both a prophylactic and a therapeutic intervention in the event of a bioterrorist attack. First, peptide sequences that are conserved between the vaccinia virus (W) and Variola (Var) genomes will be screened for immunodominant epitopes by computer-driven (EpiMatrix) analysis and confirmed using T cells from VV-immunized individuals. Second, selected epitopes will then be aligned and cloned into DNA vaccine vectors optimized for strong and sustained expression in vivo. Third, we will vaccinate HLA-transgenic mice with the DNA vaccine constructs, measuring de novo immune responses to the DNA vaccine constructs using intracellular cytokine flow cytometry. EpiVax will be responsible for selecting the VV/Var epitopes and managing the project. The TB/HIV Research Lab at Brown University (subcontractor) will perform binding assays and develop the oligonucleotide multi-epitope constructs consisting of strings of the selected epitopes. Dr. Crowe's laboratory (subcontractor, Vanderbilt University) will perform ELISpot assays. Dr. Weiner (subcontractor, Stellar Chance Laboratories, University of Pennsylvania) will perform the vaccination studies. The final product of Phase I will be an evaluation of the immunogenicity and protective effect of several prototype smallpox vaccine constructs in HLA transgenic mice. In Phase II we would screen additional epitopes, build the final vaccine constructs, optimize the immunogenicity of the final vaccine constructs with adjuvants and delivery vehicles, and address the safety, toxicity and immunogenicity of the constructs in human subjects.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government